Navigation Links
Horizon Therapeutics Names Timothy P. Walbert as President and CEO

PALO ALTO, Calif., July 24 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Timothy P. Walbert has been named president, chief executive officer and member of the board of directors of Horizon Therapeutics.

"Tim has a long, proven track record of successfully commercializing multi-billion dollar drugs in the pain and arthritis areas," said George Tidmarsh, M.D., Ph.D., founder, scientific consultant and board member of Horizon. "Tim has the perfect background to lead our company as we move toward the unblinding of the Phase 3 clinical data for our lead product candidate HZT-501, a proprietary formulation of ibuprofen combined with famotidine in a single pill. We are thrilled to have someone of his caliber joining Horizon."

Mr. Walbert has nearly two decades of executive, general management, marketing and sales experience in the pharmaceutical and biotech industries. Mr. Walbert is currently president and chief executive officer of IDM Pharma (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Prior to IDM Pharma, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc.

Mr. Walbert previously was at Abbott where he served as divisional vice president and general manager of Abbott Immunology and divisional vice president of global cardiovascular marketing. Under his leadership, he was responsible for the creation of Abbott Immunology through the approval, launch and commercialization of HUMIRA(R) for the treatment of rheumatoid arthritis in the United States, Europe and other countries. HUMIRA became the most successful launch in Abbott's history, achieving sales of more than $1.4 billion by 2005 and is expected to exceed $3 billion in 2008.

Mr. Walbert also served as director, Celebrex(R) North America and arthritis team leader, Asia Pacific, Latin America and Canada at Searle/Pharmacia. He coordinated Celebrex activities in Canada, Australia, and Latin America where aggregate sales grew to nearly $400 million in 2000, making it one of the most successful pharmaceutical products launched in many of those countries. Mr. Walbert also held a number of other key marketing and sales positions with Searle/Pharmacia, which included the U.S. launch of Arthrotec(R), a combination arthritis/pain product which generated more than $200 million in first year sales in 1998 and Daypro(R), an arthritis/pain product which generated more than $300 million in peak U.S. sales.

"I am excited by the opportunity to lead Horizon and help bring a new therapeutic option to market that may offer patients effective pain relief with GI-protection," said Mr. Walbert. "Approximately 25 percent of regular NSAID users may develop stomach ulcers and there continues to be a significant unmet treatment need for effective pain relief while lowering a patient's risk of developing these ulcers. Horizon is well positioned to address this need and become a market leader."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy, and patient compliance. For more information about the company and its products, please visit

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wins 7th Annual Horizon Interactive Award
2. New possibilities for breast cancer treatment on the horizon
3. Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
4. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
5. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
6. Horizon Organic(R) Family Farmer Network Grows by Nearly 35 Percent
7. BioHorizons Expands to New 44,000 Square Foot Facility
8. BioHorizons Introduces Its New Tapered Internal Implants Featuring Laser-Lok(R) Microgrooves
9. NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality
10. Targets on the horizon: Emerging therapies and novel targets
11. HORIZONS AMI trial data will help set guidelines
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... "Self Administration of High Viscosity Drugs" report ... has announced the addition of the "Self ... their offering. --> Research and Markets ... the "Self Administration of High Viscosity Drugs" ...
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology: